1
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Bailes M, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, et alAbbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Bailes M, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bossie K, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia H, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung AKW, Chung S, Ciani G, Ciolfi R, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, De S, DeBra D, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Dergachev V, De Rosa R, DeRosa RT, De Rossi C, DeSalvo R, de Varona O, Devenson J, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Renzo F, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Ducrot M, Dudi R, Dupej P, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenstein RA, Essick RC, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finstad D, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries EM, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard H, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia-Quiros C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glover L, Goetz E, Goetz R, Gomes S, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hinderer T, Ho WCG, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Hu YM, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Kastaun W, Katolik M, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Kent C, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimbrell SJ, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Larson SL, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leon E, Leonardi M, Leroy N, Letendre N, Levin Y, Li TGF, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsh P, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Marx JN, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIntyre G, McIver J, McManus DJ, McNeill L, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller BB, Miller J, Millhouse M, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Moggi A, Mogushi K, Mohan M, Mohapatra SRP, Molina I, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Morriss SR, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Newton G, Ng KKY, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, North C, Nuttall LK, Oberling J, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poe M, Poggiani R, Popolizio P, Porter EK, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Reyes SD, Ricci F, Ricker PM, Rieger S, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sonnenberg JA, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Wessel EK, Weßels P, Westerweck J, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford J, Wong KWK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral. PHYSICAL REVIEW LETTERS 2017; 119:161101. [PMID: 29099225 DOI: 10.1103/physrevlett.119.161101] [Show More Authors] [Citation(s) in RCA: 890] [Impact Index Per Article: 111.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Indexed: 05/21/2023]
Abstract
On August 17, 2017 at 12∶41:04 UTC the Advanced LIGO and Advanced Virgo gravitational-wave detectors made their first observation of a binary neutron star inspiral. The signal, GW170817, was detected with a combined signal-to-noise ratio of 32.4 and a false-alarm-rate estimate of less than one per 8.0×10^{4} years. We infer the component masses of the binary to be between 0.86 and 2.26 M_{⊙}, in agreement with masses of known neutron stars. Restricting the component spins to the range inferred in binary neutron stars, we find the component masses to be in the range 1.17-1.60 M_{⊙}, with the total mass of the system 2.74_{-0.01}^{+0.04}M_{⊙}. The source was localized within a sky region of 28 deg^{2} (90% probability) and had a luminosity distance of 40_{-14}^{+8} Mpc, the closest and most precisely localized gravitational-wave signal yet. The association with the γ-ray burst GRB 170817A, detected by Fermi-GBM 1.7 s after the coalescence, corroborates the hypothesis of a neutron star merger and provides the first direct evidence of a link between these mergers and short γ-ray bursts. Subsequent identification of transient counterparts across the electromagnetic spectrum in the same location further supports the interpretation of this event as a neutron star merger. This unprecedented joint gravitational and electromagnetic observation provides insight into astrophysics, dense matter, gravitation, and cosmology.
Collapse
|
|
8 |
890 |
2
|
Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B, Dumon H. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008; 92:272-83. [PMID: 18477307 DOI: 10.1111/j.1439-0396.2007.00752.x] [Citation(s) in RCA: 643] [Impact Index Per Article: 37.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The liver plays a key role in lipid metabolism. Depending on species it is, more or less, the hub of fatty acid synthesis and lipid circulation through lipoprotein synthesis. Eventually the accumulation of lipid droplets into the hepatocytes results in hepatic steatosis, which may develop as a consequence of multiple dysfunctions such as alterations in beta-oxidation, very low density lipoprotein secretion, and pathways involved in the synthesis of fatty acids. In addition an increased circulating pool of non-esterified fatty acid may also to be a major determinant in the pathogenesis fatty liver disease. This review also focuses on transcription factors such as sterol-regulatory-element-binding protein-1c and peroxisome proliferator-activated receptor alpha, which promote either hepatic fatty acid synthesis or oxidation.
Collapse
|
Review |
17 |
643 |
3
|
Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997; 45:387-393. [PMID: 9165320 DOI: 10.1016/s0016-5107(97)70149-4] [Citation(s) in RCA: 452] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) of pancreatic lesions is being increasingly used. Our aim was to determine the safety, accuracy, and clinical utility of EUS-guided FNA in both the diagnosis and staging of pancreatic cancer. METHODS Forty-four patients (24 men/20 women) had EUS-guided FNA of pancreatic lesions (39 head/neck, 5 body, 3 tail) and/or associated lymph nodes. The mean age was 61 (range, 28 to 88 years). The indication for EUS-guided FNA was a pancreatic lesion seen initially on CT (39%), ERCP (43%), or EUS (18%). Follow-up data were collected on all patients for mean of 14.5 months (range 1 to 33 months). RESULTS CT detected only 15 of 61 (25%) focal lesions seen by EUS, Adequate specimens were obtained by EUS-guided FNA in 44 of 47 (94%) pancreatic lesions and 14 of 14 (100%) associated lymph nodes (overall adequacy was 95%). Of the 46 lesions in which specimens were adequate and a final diagnosis was available (32 malignant, 14 benign), EUS-guided FNA had a sensitivity of 92%, specificity of 100%, and diagnostic accuracy of 95% for pancreatic lesions and 83%, 100%, and 88% for lymph nodes, respectively. Six percent of pancreatic cases had inadequate specimens and, if included, lowered the sensitivity to 83%, specificity to 80%, and diagnostic accuracy to 88% for pancreatic lesions. In 3 patients with enlarged celiac nodes on EUS, EUS-guided FNA was able to make a tissue diagnosis of metastasis, which changed the preoperative staging and precluded surgery. EUS in combination with EUS-guided FNA precluded surgery in 12 of 44 (27%) and may have precluded surgery in an additional 6 of 44 (14%). EUS-guided FNA avoided the need for further diagnostic tests, thus expediting therapy in a total of 25 (57%) patients and influenced clinical decisions in 30 of 44 (68%) patients. The estimated cost savings based on surgeries avoided was approximately $3300 per patient. There was only one complication (2%), a post-FNA fever. CONCLUSION EUS-guided FNA of the pancreas appears to be a safe and effective method that increases both the diagnostic and staging capability of EUS in pancreatic cancer. The clinical impact of EUS-guided FNA includes avoiding surgery and additional imaging studies with a substantial cost savings.
Collapse
|
|
28 |
452 |
4
|
Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem 2000; 275:3305-12. [PMID: 10652318 DOI: 10.1074/jbc.275.5.3305] [Citation(s) in RCA: 277] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The hsp90 family of molecular chaperones was expanded recently due to the cloning of TRAP1 and hsp75 by yeast two-hybrid screens. Careful analysis of the human TRAP1 and hsp75 sequences revealed that they are identical, and we have cloned a similar protein from Drosophila. Immunofluorescence data show that human TRAP1 is localized to mitochondria. This mitochondrial localization is supported by the existence of mitochondrial localization sequences in the amino termini of both the human and Drosophila proteins. Due to the striking homology of TRAP1 to hsp90, we tested the ability of TRAP1 to function as an hsp90-like chaperone. TRAP1 did not form stable complexes with the classic hsp90 co-chaperones p23 and Hop (p60). Consistent with these observations, TRAP1 had no effect on the hsp90-dependent reconstitution of hormone binding to the progesterone receptor in vitro, nor could it substitute for hsp90 to promote maturation of the receptor to its hormone-binding state. However, TRAP1 is sufficiently conserved with hsp90 such that it bound ATP, and this binding was sensitive to the hsp90 inhibitor geldanamycin. In addition, TRAP1 exhibited ATPase activity that was inhibited by both geldanamycin and radicicol. Thus, TRAP1 has functions that are distinct from those of hsp90.
Collapse
|
|
25 |
277 |
5
|
Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 1998; 12:1605-18. [PMID: 9773983 DOI: 10.1210/mend.12.10.0185] [Citation(s) in RCA: 235] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Estrogen receptor-alpha contains two transactivation functions, a weak constitutive activation function (AF-1) and a hormone-dependent activation function (AF-2). AF-2 works by recruiting a large coactivator complex, composed of one or more p160s, CREB-binding protein (CBP)/p300, and P/CAF (p300 and CBP-associated factor), via direct contacts with the p160s. We report here that independent AF-1 activity also requires p160 contacts. Unlike AF-2, which binds signature NR boxes in the center of the p160 molecule, AF-1 binds to sequences near the p160 C terminus. We propose that the ability of AF-1 and AF-2 to interact with separate surfaces of the same coactivator is important for the ability of these transactivation functions to synergize.
Collapse
|
|
27 |
235 |
6
|
Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999; 13:1672-85. [PMID: 10517669 DOI: 10.1210/mend.13.10.0357] [Citation(s) in RCA: 218] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Estrogen receptors (ERs alpha and beta) enhance transcription in response to estrogens by binding to estrogen response elements (EREs) within target genes and utilizing transactivation functions (AF-1 and AF-2) to recruit p160 coactivator proteins. The ERs also enhance transcription in response to estrogens and antiestrogens by modulating the activity of the AP-1 protein complex. Here, we examine the role of AF-1 and AF-2 in ER action at AP-1 sites. Estrogen responses at AP-1 sites require the integrity of the ERalpha AF-1 and AF-2 activation surfaces and the complementary surfaces on the p160 coactivator GRIP1 (glucocorticoid receptor interacting protein 1), the NID/AF-1 region, and NR boxes. Thus, estrogen-liganded ERalpha utilizes the same protein-protein contacts to transactivate at EREs and AP-1 sites. In contrast, antiestrogen responses are strongly inhibited by ERalpha AF-1 and weakly inhibited by AF-2. Indeed, ERalpha truncations that lack AF-1 enhance AP-1 activity in the presence of antiestrogens, but not estrogens. This phenotype resembles ERbeta, which naturally lacks constitutive AF-1 activity. We conclude that the ERs enhance AP-1 responsive transcription by distinct mechanisms with different requirements for ER transactivation functions. We suggest that estrogen-liganded ER enhances AP-1 activity via interactions with p160s and speculate that antiestrogen-liganded ER enhances AP-1 activity via interactions with corepressors.
Collapse
|
|
26 |
218 |
7
|
Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996; 16:5839-45. [PMID: 8816498 PMCID: PMC231585 DOI: 10.1128/mcb.16.10.5839] [Citation(s) in RCA: 209] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The serine/threonine kinase Raf-1 functions downstream of Rats in a signal transduction cascade which transmits mitogenic stimuli from the plasma membrane to the nucleus. Raf-1 integrates signals coming from extracellular factors and, in turn, activates its substrate, MEK kinase. MEK activates mitogen-activated protein kinase (MAPK), which phosphorylates other kinases as well as transcription factors. Raf-1 exists in a complex with HSP90 and other proteins. The benzoquinone ansamycin geldanamycin (GA) binds to HSP90 and disrupts the Raf-1-HSP90 multimolecular complex, leading to destabilization of Raf-1. In this study, we examined whether Raf-1 destabilization is sufficient to block the Raf-1-MEK-MAPK signalling pathway and whether GA specifically inactivates the Raf-1 component of this pathway. Using the model system of NIH 3T3 cells stimulated with phorbol 12-myristate 13-acetate (PMA), we show that GA does not affect the ability of protein kinase C alpha to be activated by phorbol esters, but it does block activation of MEK and MAPK. Further, GA does not decrease the activity of constitutively active MEK in transiently transfected cells. Finally, disruption of the Raf-1-MEK-MAPK signalling pathway by GA prevents both the PMA-induced proliferative response and PMA-induced activation of a MAPK-sensitive nuclear transcription factor. Thus, we demonstrate that interaction between HSP90 and Raf-1 is a sine qua non for Raf stability and function as a signal transducer and that the effects observed cannot be attributed to a general impairment of protein kinase function.
Collapse
|
research-article |
29 |
209 |
8
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, et alAbbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia A, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Giazotto A, Gill K, Giordano G, Glover L, Goetz E, Goetz R, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Green R, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Gulati HK, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hamilton HF, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Hernandez FJ, Heurs M, Hild S, Hinderer T, Ho WCG, Hoak D, Hochheim S, Hofman D, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Huerta EA, Huet D, Hughey B, Hulko M, Husa S, Huttner SH, Huynh-Dinh T, Iess A, Indik N, Ingram C, Inta R, Intini G, Irwin BS, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Johnson DS, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katolik M, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Keerthana NV, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Key JS, Khalili FY, Khamesra B, Khan H, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Landry P, Lang RN, Lange J, Lantz B, Lanza RK, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leonardi M, Leroy N, Letendre N, Levin Y, Li J, Li TGF, Li X, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Mereni L, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Mills J, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Mogushi K, Mohan M, Mohapatra SRP, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Ng KY, Ng S, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, North C, Nuttall LK, Obergaulinger M, Oberling J, O'Brien BD, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedersen C, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perego A, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poggiani R, Popolizio P, Porter EK, Possenti L, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Principe M, Privitera S, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Ricci F, Ricker PM, Riemenschneider GM, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Robson T, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sarin N, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Shen H, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Slaven-Blair TJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Steltner B, Stevenson SP, Stocks D, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trovato A, Trozzo L, Tsang KW, Tse M, Tso R, Tsuna D, Tsukada L, Tuyenbayev D, Ueno K, Ugolini D, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Wessel EK, Weßels P, Westerweck J, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong WK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yam W, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zlochower Y, Zucker ME, Zweizig J. GW170817: Measurements of Neutron Star Radii and Equation of State. PHYSICAL REVIEW LETTERS 2018; 121:161101. [PMID: 30387654 DOI: 10.1103/physrevlett.121.161101] [Show More Authors] [Citation(s) in RCA: 198] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 07/25/2018] [Indexed: 06/08/2023]
Abstract
On 17 August 2017, the LIGO and Virgo observatories made the first direct detection of gravitational waves from the coalescence of a neutron star binary system. The detection of this gravitational-wave signal, GW170817, offers a novel opportunity to directly probe the properties of matter at the extreme conditions found in the interior of these stars. The initial, minimal-assumption analysis of the LIGO and Virgo data placed constraints on the tidal effects of the coalescing bodies, which were then translated to constraints on neutron star radii. Here, we expand upon previous analyses by working under the hypothesis that both bodies were neutron stars that are described by the same equation of state and have spins within the range observed in Galactic binary neutron stars. Our analysis employs two methods: the use of equation-of-state-insensitive relations between various macroscopic properties of the neutron stars and the use of an efficient parametrization of the defining function p(ρ) of the equation of state itself. From the LIGO and Virgo data alone and the first method, we measure the two neutron star radii as R_{1}=10.8_{-1.7}^{+2.0} km for the heavier star and R_{2}=10.7_{-1.5}^{+2.1} km for the lighter star at the 90% credible level. If we additionally require that the equation of state supports neutron stars with masses larger than 1.97 M_{⊙} as required from electromagnetic observations and employ the equation-of-state parametrization, we further constrain R_{1}=11.9_{-1.4}^{+1.4} km and R_{2}=11.9_{-1.4}^{+1.4} km at the 90% credible level. Finally, we obtain constraints on p(ρ) at supranuclear densities, with pressure at twice nuclear saturation density measured at 3.5_{-1.7}^{+2.7}×10^{34} dyn cm^{-2} at the 90% level.
Collapse
|
|
7 |
198 |
9
|
Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A 1994; 91:5330-5334. [PMID: 8202489 PMCID: PMC43988 DOI: 10.1073/pnas.91.12.5330] [Citation(s) in RCA: 193] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Recent clinicopathologic studies have shown that many prostatic adenocarcinomas express focal neuroendocrine differentiation and that neuroendocrine differentiation is most apparent in advanced anaplastic tumors. While studying growth-regulatory signal transduction events in human prostate carcinoma cell lines, we found that in two of four cell lines, the androgen-sensitive line LNCaP and the highly metastatic androgen-independent line PC-3-M, elevation of cAMP through addition of cAMP analogues or phosphodiesterase inhibitors induced a markedly neuronal morphology. Also in LNCaP cells ultrastructural analysis showed that cAMP induced the appearance of neurosecretory cell-like dense-core granules. Phenotypic analysis of untreated LNCaP and PC-3-M cells showed that both cell lines express markers of the neural crest including S-100, chromogranin A, pp60c-src, and neuron-specific enolase as well as the epithelial marker KS1/4 and stage-specific embryonic antigen 4. In PC-3-M cells, cAMP markedly elevated neuron-specific enolase protein and caused an increase in the specific activity of the neuroendocrine marker pp60c-src, and in both cell lines expression of KS1/4 and stage-specific embryonic antigen 4 was down-regulated. In addition to effects on lineage markers, cAMP treatment induced G1 synchronization, growth arrest, and loss of clonogenicity, indicating terminal differentiation. Our data provide direct evidence of plasticity in the lineage commitment of adenocarcinoma of the prostate. We have shown that cell-permeant cAMP analogues can induce terminal differentiation, suggesting that hydrolysis-resistant cyclic nucleotides may present an additional approach to the treatment of advanced prostate cancer.
Collapse
|
research-article |
31 |
193 |
10
|
Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996; 271:4974-7. [PMID: 8617772 DOI: 10.1074/jbc.271.9.4974] [Citation(s) in RCA: 187] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Treatment of SKBr3 cells with benzoquinone ansamycins, such as geldanamycin (GA), depletes p185erbB2, the receptor tyrosine kinase encoded by the erbB2 gene. In the same cells, a biologically active benzoquinone photoaffinity label specifically binds a protein of about 100 kDa, and the ability of various GA derivatives to reduce the intracellular level of p185erbB2 correlates with their ability to compete with the photoaffinity label for binding to this protein. In this report, we present evidence that the approximately 100-kDa ansamycin-binding protein is GRP94. Membrane-associated p185erbB2 exists in a stable complex with GRP94. GA binding to GRP94 disrupts this complex, leading to degradation of pre-existing p185erbB2 protein, and resulting in an altered subcellular distribution of newly synthesized p185erbB2.
Collapse
|
|
29 |
187 |
11
|
Abstract
Growth impairment is a common complication of childhood Crohn's disease, but longitudinal data and follow up studies into adulthood are sparse. This study reviewed the records of 100 Tanner stages 1 and 2 children (66 males, 34 females) consecutively diagnosed with Crohn's disease at this hospital between January 1980 and June 1988. The influence of sex, anatomical location of disease, severity of symptoms, corticosteroids, and surgical intervention on growth were analysed by univariate and multivariate regression analysis. At diagnosis mean standard deviation score (SDS) for height was -1.11 (1.28) (males -1.14 (1.26), females -1.05 (1.33)). Twenty one children were below the third centile for height. During years one and two height velocity (cm/y) was 4.4 (2.3) and 5.1 (2.7), but 40% of children in year one and 33% of children in year two grew less than expected (< 4 cm). Forty nine children grew < 4 cm/y during two or more of the 4.9 (1.8) years of follow up. Severity of gastrointestinal symptoms was the major factor influencing linear growth velocity (p < 0.01 for years one and two). Despite the high prevalence of growth impairment, the subset of children who had reached maturity by the time of the study (n = 67) nevertheless maintained their height centile. The SDS for height at ultimate follow up was -0.82 (1.1). Compared with diagnosis, change in SDS was +0.35 (1.08). Growth increments were comparable for surgically treated patients v patients only treated medically and among patients stratified by location of disease. Females (n = 25) achieved greater catch up growth than males (n = 42). Ultimate SDS for height for females was -0.48 (0.91) v -1.02 (1.19) for males. Change in SDS for height was +0.66 (1.27) for females v +0.16 (0.90) for males (p=0.02). These data confirm the frequency of growth impairment in childhood Crohn's disease. After diagnosis, however, the prognosis for ultimate linear growth is good.
Collapse
|
research-article |
32 |
177 |
12
|
Tripp RA, Hamilton-Easton AM, Cardin RD, Nguyen P, Behm FG, Woodland DL, Doherty PC, Blackman MA. Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med 1997; 185:1641-50. [PMID: 9151901 PMCID: PMC2196306 DOI: 10.1084/jem.185.9.1641] [Citation(s) in RCA: 137] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/1996] [Revised: 02/25/1997] [Indexed: 02/04/2023] Open
Abstract
The murine gamma-herpesvirus 68 has many similarities to EBV, and induces a syndrome comparable to infectious mononucleosis (IM). The frequency of activated CD8+ T cells (CD62L(lo)) in the peripheral blood increased greater than fourfold by 21 d after infection of C57BL/6J (H-2(b)) mice, and remained high for at least a further month. The spectrum of T cell receptor usage was greatly skewed, with as many as 75% of the CD8+ T cells in the blood expressing a Vbeta4+ phenotype. Interestingly, the Vbeta4 dominance was also seen, to varying extents, in H-2(k), H-2(d), H-2(u), and H-2(q) strains of mice. In addition, although CD4 depletion from day 11 had no effect on the Vbeta4 bias of the T cells, the Vbeta4+CD8+ expansion was absent in H-2IA(b)-deficient congenic mice. However, the numbers of cycling cells in the CD4 antibody-depleted mice and mice that are CD4 deficient as a consequence of the deletion of MHC class II, were generally lower. The findings suggest that the IM-like disease is driven both by cytokines provided by CD4+ T cells and by a viral superantigen presented by MHC class II glycoproteins to Vbeta4+CD8+ T cells.
Collapse
|
research-article |
28 |
137 |
13
|
Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 1995; 763:22-42. [PMID: 7677333 DOI: 10.1111/j.1749-6632.1995.tb32388.x] [Citation(s) in RCA: 136] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Data were presented showing that I1-imidazoline sites show a unique ligand specificity that differs markedly from that of any of the alpha 2-adrenergic subtypes or the I2-imidazoline sites labeled by [3H]idazoxan. On the other hand, the ligand specificity of I1-imidazoline sites is maintained across mammalian species (cow, rat, dog, and human) and between different tissues and cell types. I1-Imidazoline sites can be further distinguished from I2 sites because the latter, unlike I1 sites, were not present in RVLM membranes from bovine brain stem. Furthermore, I1-imidazoline sites were modulated by guanine nucleotides with a specificity appropriate for a receptor coupled to G-protein and were mainly localized to plasma membranes. I1-Imidazoline sites show a unique pattern of distribution between diverse tissues and cell types and appear to be a neuroepithelial marker as well as being present in secretory cells of the pancreatic islets. The widespread distribution of I1-imidazoline sites implies that the functional significance of this putative receptor may have been underestimated. The signaling pathway associated with the I1-imidazoline receptor remains to be fully elucidated, but is likely that activation of phospholipase A2 leading to release of arachidonic acid and subsequent generation of prostaglandins plays a major role.
Collapse
|
Review |
30 |
136 |
14
|
Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998; 273:10618-23. [PMID: 9553123 DOI: 10.1074/jbc.273.17.10618] [Citation(s) in RCA: 133] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Progression through the cell cycle is controlled by the induction of cyclins and the activation of cognate cyclin-dependent kinases. The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor lovastatin induces growth arrest and cell death in certain cancer cell types. We have pursued the mechanism of growth arrest in PC-3-M cells, a p53-null human prostate carcinoma cell line. Lovastatin treatment increased protein and mRNA levels of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1), increased binding of p21 with Cdk2, markedly inhibited cyclin E- and Cdk2-associated phosphorylation of histone H1 or GST-retinoblastoma protein, enhanced binding of the retinoblastoma protein to the transcription factor E2F-1 in vivo, and induced the activation of a p21 promoter reporter construct. By using p21 promoter deletion constructs, the lovastatin-responsive element was mapped to a region between -93 and -64 relative to the transcription start site. Promoter mutation analysis indicated that the lovastatin-responsive site coincided with the previously identified transforming growth factor-beta-responsive element. These data indicate that in human prostate carcinoma cells an inhibitor of the HMG-CoA reductase pathway can circumvent the loss of wild-type p53 function and induce critical downstream regulatory events leading to transcriptional activation of p21.
Collapse
|
|
27 |
133 |
15
|
Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:6821-6. [PMID: 11739498 DOI: 10.4049/jimmunol.167.12.6821] [Citation(s) in RCA: 124] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Neutralization of TNF-alpha in humans with rheumatoid arthritis or Crohn's disease has been associated with the development of humoral autoimmunity. To determine the effect of TNF-alpha neutralization on cell-mediated and humoral-mediated responses, we administered anti-TNF-alpha mAb to mice undergoing acute graft-vs-host disease (GVHD) using the parent-into-F(1) model. In vivo neutralization of TNF-alpha blocked the lymphocytopenic features characteristic of acute GVHD and induced a lupus-like chronic GVHD phenotype (lymphoproliferation and autoantibody production). These effects resulted from complete inhibition of detectable antihost CTL activity and required the presence of anti-TNF-alpha mAb for the first 4 days after parental cell transfer, indicating that TNF-alpha plays a critical role in the induction of CTL. Moreover, an in vivo blockade of TNF-alpha preferentially inhibited the production of IFN-gamma and blocked IFN-gamma-dependent up-regulation of Fas; however, cytokines such as IL-10, IL-6, or IL-4 were not inhibited. These results suggest that a therapeutic TNF-alpha blockade may promote humoral autoimmunity by selectively inhibiting the induction of a CTL response that would normally suppress autoreactive B cells.
Collapse
|
|
24 |
124 |
16
|
Tse M, Yu H, Kijbunchoo N, Fernandez-Galiana A, Dupej P, Barsotti L, Blair CD, Brown DD, Dwyer SE, Effler A, Evans M, Fritschel P, Frolov VV, Green AC, Mansell GL, Matichard F, Mavalvala N, McClelland DE, McCuller L, McRae T, Miller J, Mullavey A, Oelker E, Phinney IY, Sigg D, Slagmolen BJJ, Vo T, Ward RL, Whittle C, Abbott R, Adams C, Adhikari RX, Ananyeva A, Appert S, Arai K, Areeda JS, Asali Y, Aston SM, Austin C, Baer AM, Ball M, Ballmer SW, Banagiri S, Barker D, Bartlett J, Berger BK, Betzwieser J, Bhattacharjee D, Billingsley G, Biscans S, Blair RM, Bode N, Booker P, Bork R, Bramley A, Brooks AF, Buikema A, Cahillane C, Cannon KC, Chen X, Ciobanu AA, Clara F, Cooper SJ, Corley KR, Countryman ST, Covas PB, Coyne DC, Datrier LEH, Davis D, Di Fronzo C, Driggers JC, Etzel T, Evans TM, Feicht J, Fulda P, Fyffe M, Giaime JA, Giardina KD, Godwin P, Goetz E, Gras S, Gray C, Gray R, Gupta A, Gustafson EK, Gustafson R, Hanks J, Hanson J, Hardwick T, Hasskew RK, Heintze MC, Helmling-Cornell AF, Holland NA, Jones JD, Kandhasamy S, Karki S, Kasprzack M, Kawabe K, King PJ, Kissel JS, et alTse M, Yu H, Kijbunchoo N, Fernandez-Galiana A, Dupej P, Barsotti L, Blair CD, Brown DD, Dwyer SE, Effler A, Evans M, Fritschel P, Frolov VV, Green AC, Mansell GL, Matichard F, Mavalvala N, McClelland DE, McCuller L, McRae T, Miller J, Mullavey A, Oelker E, Phinney IY, Sigg D, Slagmolen BJJ, Vo T, Ward RL, Whittle C, Abbott R, Adams C, Adhikari RX, Ananyeva A, Appert S, Arai K, Areeda JS, Asali Y, Aston SM, Austin C, Baer AM, Ball M, Ballmer SW, Banagiri S, Barker D, Bartlett J, Berger BK, Betzwieser J, Bhattacharjee D, Billingsley G, Biscans S, Blair RM, Bode N, Booker P, Bork R, Bramley A, Brooks AF, Buikema A, Cahillane C, Cannon KC, Chen X, Ciobanu AA, Clara F, Cooper SJ, Corley KR, Countryman ST, Covas PB, Coyne DC, Datrier LEH, Davis D, Di Fronzo C, Driggers JC, Etzel T, Evans TM, Feicht J, Fulda P, Fyffe M, Giaime JA, Giardina KD, Godwin P, Goetz E, Gras S, Gray C, Gray R, Gupta A, Gustafson EK, Gustafson R, Hanks J, Hanson J, Hardwick T, Hasskew RK, Heintze MC, Helmling-Cornell AF, Holland NA, Jones JD, Kandhasamy S, Karki S, Kasprzack M, Kawabe K, King PJ, Kissel JS, Kumar R, Landry M, Lane BB, Lantz B, Laxen M, Lecoeuche YK, Leviton J, Liu J, Lormand M, Lundgren AP, Macas R, MacInnis M, Macleod DM, Márka S, Márka Z, Martynov DV, Mason K, Massinger TJ, McCarthy R, McCormick S, McIver J, Mendell G, Merfeld K, Merilh EL, Meylahn F, Mistry T, Mittleman R, Moreno G, Mow-Lowry CM, Mozzon S, Nelson TJN, Nguyen P, Nuttall LK, Oberling J, Oram RJ, O'Reilly B, Osthelder C, Ottaway DJ, Overmier H, Palamos JR, Parker W, Payne E, Pele A, Perez CJ, Pirello M, Radkins H, Ramirez KE, Richardson JW, Riles K, Robertson NA, Rollins JG, Romel CL, Romie JH, Ross MP, Ryan K, Sadecki T, Sanchez EJ, Sanchez LE, Saravanan TR, Savage RL, Schaetzl D, Schnabel R, Schofield RMS, Schwartz E, Sellers D, Shaffer TJ, Smith JR, Soni S, Sorazu B, Spencer AP, Strain KA, Sun L, Szczepańczyk MJ, Thomas M, Thomas P, Thorne KA, Toland K, Torrie CI, Traylor G, Urban AL, Vajente G, Valdes G, Vander-Hyde DC, Veitch PJ, Venkateswara K, Venugopalan G, Viets AD, Vorvick C, Wade M, Warner J, Weaver B, Weiss R, Willke B, Wipf CC, Xiao L, Yamamoto H, Yap MJ, Yu H, Zhang L, Zucker ME, Zweizig J. Quantum-Enhanced Advanced LIGO Detectors in the Era of Gravitational-Wave Astronomy. PHYSICAL REVIEW LETTERS 2019; 123:231107. [PMID: 31868462 DOI: 10.1103/physrevlett.123.231107] [Show More Authors] [Citation(s) in RCA: 124] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Indexed: 06/10/2023]
Abstract
The Laser Interferometer Gravitational Wave Observatory (LIGO) has been directly detecting gravitational waves from compact binary mergers since 2015. We report on the first use of squeezed vacuum states in the direct measurement of gravitational waves with the Advanced LIGO H1 and L1 detectors. This achievement is the culmination of decades of research to implement squeezed states in gravitational-wave detectors. During the ongoing O3 observation run, squeezed states are improving the sensitivity of the LIGO interferometers to signals above 50 Hz by up to 3 dB, thereby increasing the expected detection rate by 40% (H1) and 50% (L1).
Collapse
|
|
6 |
124 |
17
|
Nguyen P, Feng JC, Chang KJ. Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (FNA) of liver lesions. Gastrointest Endosc 1999; 50:357-361. [PMID: 10462656 DOI: 10.1053/ge.1999.v50.97208] [Citation(s) in RCA: 121] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Endoscopic ultrasonography (EUS) is not traditionally thought to be clinically applicable in liver imaging. EUS-guided fine-needle aspiration of the liver has not been well described. METHODS A prospective study was conducted in which 574 consecutive patients with a history or suspicion of gastrointestinal or pulmonary malignant tumor undergoing upper EUS examinations underwent EUS evaluation of the liver. Fourteen (2.4%) patients were found to have focal liver lesions and underwent EUS-guided fine-needle aspiration. RESULTS The median largest diameter of the liver lesions was 1.1 cm (range 0.8 to 5.2 cm). The mean number of passes was 2.0 (range 1 to 5 passes). All fine-needle passes yielded an adequate specimen. One of the 14 patients underwent EUS-guided fine-needle aspiration of 2 liver lesions. Fourteen of the 15 liver lesions sampled by means of EUS-guided fine-needle aspiration were malignant and one was benign. Before EUS, computed tomography (CT) depicted liver lesions in only 3 of 14 (21%) patients. Seven of 14 patients had a known cancer diagnosis. For the other 7, the initial diagnosis of cancer was made by means of EUS-guided fine-needle aspiration of the liver. There were no immediate or late complications. CONCLUSIONS EUS can detect small focal liver lesions that are not detected at CT. Findings of EUS-guided fine-needle aspiration can confirm a cytologic diagnosis of liver metastasis and establish a definitive M stage that may change clinical management.
Collapse
|
Clinical Trial |
26 |
121 |
18
|
Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB. Regulation of cyclin D1 by calpain protease. J Biol Chem 1997; 272:28479-84. [PMID: 9353308 DOI: 10.1074/jbc.272.45.28479] [Citation(s) in RCA: 113] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Cyclin D1, a critical positive regulator of G1 progression, has been implicated in the pathogenesis of certain cancers. Regulation of cyclin D1 occurs at the transcriptional and posttranscriptional level. Here we present evidence that cyclin D1 levels are regulated at the posttranscriptional level by the Ca2+-activated protease calpain. Serum starvation of NIH 3T3 cells resulted in rapid loss of cyclin D1 protein that was completely reversible by calpain inhibitors. Actinomycin D and lovastatin induced rapid loss of cyclin D1 in prostate and breast cancer cells that was reversible by calpain inhibitors and not by phenylmethylsulfonyl fluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26 S proteasome. Treatment of intact NIH 3T3, prostate, and breast cancer cells with a calpain inhibitor dramatically increased the half-life of cyclin D1 protein. Addition of purified calpain to PC-3-M lysates resulted in Ca2+-dependent cyclin D1 degradation. Transient expression of the calpain inhibitor calpastatin increased cyclin D1 protein in serum-starved NIH 3T3 cells. Cyclins A, E, and B1 have been reported to be regulated by proteasome-associated proteolysis. The data presented here implicate calpain in cyclin D1 posttranslational regulation.
Collapse
|
|
28 |
113 |
19
|
Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ. The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol Endocrinol 2000; 14:1976-85. [PMID: 11117528 DOI: 10.1210/mend.14.12.0566] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Unliganded thyroid hormone receptors (TRs) repress transcription through recruitment of corepressors, including nuclear receptor corepressor (N-CoR). We find that N-CoR contains three interaction domains (IDs) that bind to TR, rather than the previously reported two. The hitherto unrecognized ID (ID3) serves as a fully functional TR binding site, both in vivo and in vitro, and may be the most important for TR binding. Each ID motif contains a conserved hydrophobic core (I/LXXII) that resembles the hydrophobic core of nuclear receptor boxes (LXXLL), which mediates p160 coactivator binding to liganded nuclear receptors. Although the integrity of the I/LXXII motif is required for ID function, substitution of ID isoleucines with leucines did not allow ID peptides to bind to liganded TR, and substitution of NR box leucines with isoleucines did not allow NR box peptides to bind unliganded TR. This indicates that the binding preferences of N-CoR for unliganded TR and p160s for liganded TR are not dictated solely by the identity of conserved hydrophobic residues within their TR binding motifs. Examination of sequence conservation between IDs, and mutational analysis of individual IDs, suggests that they are comprised of the central hydrophobic core and distinct adjacent sequences that may make unique contacts with the TR surface. Accordingly, a hybrid peptide that contains distinct adjacent sequences from ID3 and ID1 shows enhanced binding to TR.
Collapse
|
|
25 |
92 |
20
|
Shustov A, Luzina I, Nguyen P, Papadimitriou JC, Handwerger B, Elkon KB, Via CS. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J Clin Invest 2000; 106:R39-47. [PMID: 10995792 PMCID: PMC381389 DOI: 10.1172/jci8876] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
To determine the role of perforin-mediated cytotoxic T lymphocyte (CTL) effector function in immune regulation, we studied a well-characterized mouse model of graft-versus-host disease (GVHD). Induction of acute GVHD using perforin-deficient donor T cells (pfp-->F1) initially resulted in features of acute GVHD, e.g., engraftment of both donor CD4(+) and CD8(+) T cells, upregulation of Fas and FasL, production of antihost CTL, and secretion of both Th1 and Th2 cytokines. Despite fully functional FasL activity, pfp donor cells failed to totally eliminate host B cells, and, by 4 weeks of disease, cytokine production in pfp-->F1 mice had polarized to a Th2 response. Pfp-->F1 mice eventually developed features of chronic GVHD, such as increased numbers of B cells, persistence of donor CD4 T cells, autoantibody production, and lupuslike renal disease. We conclude that in the setting of B- and T-cell activation, perforin plays an important immunoregulatory role in the prevention of humoral autoimmunity through the elimination of both autoreactive B cells and ag-specific T cells. Moreover, an ineffective initial CTL response can evolve into a persistent antibody-mediated response and, with it, the potential for sustained humoral autoimmunity.
Collapse
|
research-article |
25 |
81 |
21
|
Mitchison T, Wühr M, Nguyen P, Ishihara K, Groen A, Field C. Growth, interaction, and positioning of microtubule asters in extremely large vertebrate embryo cells. Cytoskeleton (Hoboken) 2012; 69:738-50. [PMID: 22786885 PMCID: PMC3690567 DOI: 10.1002/cm.21050] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2012] [Revised: 06/27/2012] [Accepted: 06/28/2012] [Indexed: 01/03/2023]
Abstract
Ray Rappaport spent many years studying microtubule asters, and how they induce cleavage furrows. Here, we review recent progress on aster structure and dynamics in zygotes and early blastomeres of Xenopus laevis and Zebrafish, where cells are extremely large. Mitotic and interphase asters differ markedly in size, and only interphase asters span the cell. Growth of interphase asters occurs by a mechanism that allows microtubule density at the aster periphery to remain approximately constant as radius increases. We discuss models for aster growth, and favor a branching nucleation process. Neighboring asters that grow into each other interact to block further growth at the shared boundary. We compare the morphology of interaction zones formed between pairs of asters that grow out from the poles of the same mitotic spindle (sister asters) and between pairs not related by mitosis (non-sister asters) that meet following polyspermic fertilization. We argue growing asters recognize each other by interaction between antiparallel microtubules at the mutual boundary, and discuss models for molecular organization of interaction zones. Finally, we discuss models for how asters, and the centrosomes within them, are positioned by dynein-mediated pulling forces so as to generate stereotyped cleavage patterns. Studying these problems in extremely large cells is starting to reveal how general principles of cell organization scale with cell size.
Collapse
|
Research Support, N.I.H., Extramural |
13 |
75 |
22
|
Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol 2001; 15:32-45. [PMID: 11145737 DOI: 10.1210/mend.15.1.0590] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Estrogen receptor (ER) is activated either by ligand or by signals from tyrosine kinase-linked cell surface receptors. We investigated whether the nonreceptor Src tyrosine kinase could affect ER activity. Expression of constitutively active Src or stimulation of the endogenous Src/JNK pathway enhances transcriptional activation by the estrogen-ER complex and strongly stimulates the otherwise weak activation by the unliganded ER and the tamoxifen-ER complex. Src affects ER activation function 1 (AF-1), and not ER AF-2, and does so through its tyrosine kinase activity. This effect of Src is mediated partly through a Raf/mitogen-activated ERK kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling cascade and partly through a MEKK/JNKK/JNK cascade. Although, as previously shown, Src action through activated ERK stimulates AF-1 by phosphorylation at S118, Src action through activated JNK neither leads to phosphorylation of S118 nor requires S118 for its action. We therefore suggest that the Src/JNK pathway enhances AF-1 activity by modification of ER AF-1-associated proteins. Src potentiates activation functions in CREB-binding protein (CBP) and glucocorticoid receptor interacting protein 1 (GRIP1), and we discuss the possibility that the Src/JNK pathway enhances the activity of these coactivators, which are known to mediate AF-1 action.
Collapse
|
|
24 |
74 |
23
|
Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Ansoldi S, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baer AM, Baird J, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barkett K, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Bentley JD, Bergamin F, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bidler J, Biggs E, et alAbbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Ansoldi S, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baer AM, Baird J, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barkett K, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Bentley JD, Bergamin F, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bidler J, Biggs E, Bilenko IA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Bissenbayeva G, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose S, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callaghan JD, Callister TA, Calloni E, Camp JB, Canepa M, Cannon KC, Cao H, Cao J, Carapella G, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Castañeda J, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi O, Chakravarti K, Chan C, Chan M, Chandra K, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Chen HY, Chen X, Chen Y, Cheng HP, Cheong CK, Chia HY, Chiadini F, Chierici R, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu Q, Chua S, Chung KW, Chung S, Ciani G, Ciecielag P, Cieślar M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Clesse S, Cleva F, Coccia E, Cohadon PF, Cohen D, Colleoni M, Collette CG, Collins C, Colpi M, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cunningham L, Cuoco E, Curylo M, Canton TD, Dálya G, Dana A, Daneshgaran-Bajastani LM, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Delfavero M, De Lillo N, Del Pozzo W, DeMarchi LM, D'Emilio V, Demos N, Dent T, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Durante O, D'Urso D, Dwyer SE, Easter PJ, Eddolls G, Edelman B, Edo TB, Edy O, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Ejlli A, Errico L, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Ewing BE, Fafone V, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Feicht J, Fejer MM, Feng F, Fenyvesi E, Ferguson DL, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fittipaldi R, Fitz-Axen M, Fiumara V, Flaminio R, Floden E, Flynn E, Fong H, Font JA, Forsyth PWF, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fronzè G, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gaebel SM, Gair JR, Galaudage S, Ganapathy D, Ganguly A, Gaonkar SG, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gayathri V, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giacomazzo B, Giaime JA, Giardina KD, Gibson DR, Gier C, Gill K, Glanzer J, Gniesmer J, Godwin P, Goetz E, Goetz R, Gohlke N, Goncharov B, González G, Gopakumar A, Gossan SE, Gosselin M, Gouaty R, Grace B, Grado A, Granata M, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson EM, Griggs HL, Grignani G, Grimaldi A, Grimm SJ, Grote H, Grunewald S, Gruning P, Guidi GM, Guimaraes AR, Guixé G, Gulati HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson EK, Gustafson R, Haegel L, Halim O, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hansen TJ, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hasskew RK, Haster CJ, Haughian K, Hayes FJ, Healy J, Heidmann A, Heintze MC, Heinze J, Heitmann H, Hellman F, Hello P, Hemming G, Hendry M, Heng IS, Hennes E, Hennig J, Heurs M, Hild S, Hinderer T, Hoback SY, Hochheim S, Hofgard E, Hofman D, Holgado AM, Holland NA, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Howell EJ, Hoy CG, Huang Y, Hübner MT, Huerta EA, Huet D, Hughey B, Hui V, Husa S, Huttner SH, Huxford R, Huynh-Dinh T, Idzkowski B, Iess A, Inchauspe H, Ingram C, Intini G, Isac JM, Isi M, Iyer BR, Jacqmin T, Jadhav SJ, Jadhav SP, James AL, Jani K, Janthalur NN, Jaranowski P, Jariwala D, Jaume R, Jenkins AC, Jiang J, Johns GR, Johnson-McDaniel NK, Jones AW, Jones DI, Jones JD, Jones P, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Kashyap R, Kasprzack M, Kastaun W, Katsanevas S, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Keivani A, Kennedy R, Key JS, Khadka S, Khalili FY, Khan I, Khan S, Khan ZA, Khazanov EA, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim GJ, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimball C, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Knyazev E, Koch P, Koehlenbeck SM, Koekoek G, Koley S, Kondrashov V, Kontos A, Koper N, Korobko M, Korth WZ, Kovalam M, Kozak DB, Kringel V, Krishnendu NV, Królak A, Krupinski N, Kuehn G, Kumar A, Kumar P, Kumar R, Kumar R, Kumar S, Kuo L, Kutynia A, Lackey BD, Laghi D, Lalande E, Lam TL, Lamberts A, Landry M, Lane BB, Lang RN, Lange J, Lantz B, Lanza RK, La Rosa I, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee CH, Lee HM, Lee HW, Lee J, Lee K, Lehmann J, Leroy N, Letendre N, Levin Y, Li AKY, Li J, Li K, Li TGF, Li X, Linde F, Linker SD, Linley JN, Littenberg TB, Liu J, Liu X, Llorens-Monteagudo M, Lo RKL, Lockwood A, London LT, Longo A, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Ma Y, Macas R, Macfoy S, MacInnis M, Macleod DM, MacMillan IAO, Macquet A, Magaña Hernandez I, Magaña-Sandoval F, Magee RM, Majorana E, Maksimovic I, Malik A, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martinez V, Martynov DV, Masalehdan H, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Mavalvala N, Maynard E, McCann JJ, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIsaac C, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Mehta AK, Mejuto Villa E, Melatos A, Mendell G, Mercer RA, Mereni L, Merfeld K, Merilh EL, Merritt JD, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Middleton H, Milano L, Miller AL, Millhouse M, Mills JC, Milotti E, Milovich-Goff MC, Minazzoli O, Minenkov Y, Mishkin A, Mishra C, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Mo G, Mogushi K, Mohapatra SRP, Mohite SR, Molina-Ruiz M, Mondin M, Montani M, Moore CJ, Moraru D, Morawski F, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Murray PG, Nagar A, Nardecchia I, Naticchioni L, Nayak RK, Neil BF, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Ng KY, Ng S, Nguyen C, Nguyen P, Nichols D, Nichols SA, Nissanke S, Nitz A, Nocera F, Noh M, North C, Nothard D, Nuttall LK, Oberling J, O'Brien BD, Oganesyan G, Ogin GH, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Oliver M, Olivetto C, Oppermann P, Oram RJ, O'Reilly B, Ormiston RG, Ortega LF, O'Shaughnessy R, Ossokine S, Osthelder C, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Pagano G, Page MA, Pagliaroli G, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pan H, Panda PK, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Payne E, Pearlstone BL, Pechsiri TC, Pedersen AJ, Pedraza M, Pele A, Penn S, Perego A, Perez CJ, Périgois C, Perreca A, Perriès S, Petermann J, Pfeiffer HP, Phelps M, Phukon KS, Piccinni OJ, Pichot M, Piendibene M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Piotrzkowski K, Pirello M, Pitkin M, Plastino W, Poggiani R, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Powell J, Prajapati AK, Prasai K, Prasanna R, Pratten G, Prestegard T, Principe M, Prodi GA, Prokhorov L, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quinonez PJ, Raab FJ, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Rafferty H, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rana J, Rao K, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Rettegno P, Ricci F, Richardson CJ, Richardson JW, Ricker PM, Riemenschneider G, Riles K, Rizzo M, Robertson NA, Robinet F, Rocchi A, Rodriguez-Soto RD, Rolland L, Rollins JG, Roma VJ, Romanelli M, Romano R, Romel CL, Romero-Shaw IM, Romie JH, Rose CA, Rose D, Rose K, Rosińska D, Rosofsky SG, Ross MP, Rowan S, Rowlinson SJ, Roy PK, Roy S, Roy S, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sakellariadou M, Salafia OS, Salconi L, Saleem M, Salemi F, Samajdar A, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sanders JR, Santiago KA, Santos E, Sarin N, Sassolas B, Sathyaprakash BS, Sauter O, Savage RL, Savant V, Sawant D, Sayah S, Schaetzl D, Schale P, Scheel M, Scheuer J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schulte BW, Schutz BF, Schwarm O, Schwartz E, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sennett N, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Sharifi S, Shahriar MS, Sharma A, Sharma P, Shawhan P, Shen H, Shikauchi M, Shink R, Shoemaker DH, Shoemaker DM, Shukla K, ShyamSundar S, Siellez K, Sieniawska M, Sigg D, Singer LP, Singh D, Singh N, Singha A, Singhal A, Sintes AM, Sipala V, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smetana J, Smith JR, Smith RJE, Somala S, Son EJ, Soni S, Sorazu B, Sordini V, Sorrentino F, Souradeep T, Sowell E, Spencer AP, Spera M, Srivastava AK, Srivastava V, Staats K, Stachie C, Standke M, Steer DA, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson S, Stocks D, Stops DJ, Stover M, Strain KA, Stratta G, Strunk A, Sturani R, Stuver AL, Sudhagar S, Sudhir V, Summerscales TZ, Sun L, Sunil S, Sur A, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Tanasijczuk AJ, Tanner DB, Tao D, Tápai M, Tapia A, Tapia San Martin EN, Tasson JD, Taylor R, Tenorio R, Terkowski L, Thirugnanasambandam MP, Thomas M, Thomas P, Thompson JE, Thondapu SR, Thorne KA, Thrane E, Tinsman CL, Saravanan TR, Tiwari S, Tiwari S, Tiwari V, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Tosta E Melo I, Töyrä D, Travasso F, Traylor G, Tringali MC, Tripathee A, Trovato A, Trudeau RJ, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tsutsui T, Turconi M, Ubhi AS, Udall R, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Utina AC, Vahlbruch H, Vajente G, Valdes G, Valentini M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, Van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Veske D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vivanco FH, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace GS, Wallace L, Walsh S, Wang JZ, Wang S, Wang WH, Ward RL, Warden ZA, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wellmann F, Wen L, Weßels P, Westhouse JW, Wette K, Whelan JT, Whiting BF, Whittle C, Wilken DM, Williams D, Willis JL, Willke B, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford JK, Wong ICF, Wright JL, Wu DS, Wysocki DM, Xiao L, Yamamoto H, Yang L, Yang Y, Yang Z, Yap MJ, Yazback M, Yeeles DW, Yu H, Yu H, Yuen SHR, Zadrożny AK, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhao C, Zhao G, Zhou M, Zhou Z, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW190521: A Binary Black Hole Merger with a Total Mass of 150 M_{⊙}. PHYSICAL REVIEW LETTERS 2020; 125:101102. [PMID: 32955328 DOI: 10.1103/physrevlett.125.101102] [Show More Authors] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 06/19/2020] [Accepted: 07/09/2020] [Indexed: 06/08/2023]
Abstract
On May 21, 2019 at 03:02:29 UTC Advanced LIGO and Advanced Virgo observed a short duration gravitational-wave signal, GW190521, with a three-detector network signal-to-noise ratio of 14.7, and an estimated false-alarm rate of 1 in 4900 yr using a search sensitive to generic transients. If GW190521 is from a quasicircular binary inspiral, then the detected signal is consistent with the merger of two black holes with masses of 85_{-14}^{+21} M_{⊙} and 66_{-18}^{+17} M_{⊙} (90% credible intervals). We infer that the primary black hole mass lies within the gap produced by (pulsational) pair-instability supernova processes, with only a 0.32% probability of being below 65 M_{⊙}. We calculate the mass of the remnant to be 142_{-16}^{+28} M_{⊙}, which can be considered an intermediate mass black hole (IMBH). The luminosity distance of the source is 5.3_{-2.6}^{+2.4} Gpc, corresponding to a redshift of 0.82_{-0.34}^{+0.28}. The inferred rate of mergers similar to GW190521 is 0.13_{-0.11}^{+0.30} Gpc^{-3} yr^{-1}.
Collapse
|
|
5 |
73 |
24
|
Higgins GA, Joharchi N, Nguyen P, Sellers EM. Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning. Psychopharmacology (Berl) 1992; 106:315-20. [PMID: 1533288 DOI: 10.1007/bf02245411] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The purpose of the present study was to reassess the original findings of Carboni et al. (1988) who suggested that 5-HT3 receptor antagonists may block morphine-induced place conditioning in rats. These workers used a biased protocol with treatments allocated to compartments based on initial preference. In the present study we have adopted an unbiased approach with treatments randomly assigned to conditioning compartment in a counter-balanced fashion. Thus treatments were equally paired between distinct environmental cues. Using this protocol, morphine produced a dose-related place preference (0.3-3 mg/kg SC). Thirty-minute pretreatment with the selective 5-HT3 antagonists, MDL72222 (1 mg/kg SC) and ondansetron (0.01 mg/kg SC) before morphine (1.5 mg/kg SC), significantly antagonized the place conditioning to this treatment. However, with higher doses of ondansetron (0.1-1 mg/kg SC), the antagonism of morphine-induced place preference became variable and dependent on the conditioning compartment. This was probably a reflection of the fact that ondansetron when administered alone also appeared to produce an environmentally dependent place conditioning at these doses. Therefore it is concluded that at certain doses, 5-HT3 receptor antagonists may antagonize morphine place conditioning in a manner consistent with a blockade of the appetitive effects of this drug. However, at higher doses, at least with ondansetron, this antagonism became non-specific and dependent on the training environment. It is suggested that other animal models of opioid reinforcement (e.g., self-administration) are now needed to validate the hypothesis that 5-HT3 receptor antagonists may modify opioid reward.
Collapse
|
Comparative Study |
33 |
70 |
25
|
Daly K, Nguyen P, Woodland DL, Blackman MA. Immunodominance of major histocompatibility complex class I-restricted influenza virus epitopes can be influenced by the T-cell receptor repertoire. J Virol 1995; 69:7416-22. [PMID: 7494246 PMCID: PMC189678 DOI: 10.1128/jvi.69.12.7416-7422.1995] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
We have used T-cell receptor beta-chain transgenic mice to determine the effects of a limited T-cell receptor repertoire on major histocompatibility complex class I-restricted epitope selection during the course of an influenza virus infection. Analysis of T-cell hybridomas generated from wild-type and transgenic mice demonstrated that the viral epitope recognized depended on the available T-cell receptor repertoire. Wild-type T-cell hybridomas recognized epitopes derived from the nucleoprotein and basic polymerase molecules, whereas hybridomas generated from transgenic mice recognized epitopes derived from the nonstructural protein and the matrix protein. There was no overlap in specificity between the two panels of hybridomas. This reciprocal pattern of specificity was also apparent in cytoxicity assays with brochoalveolar lavage cells isolated from the lungs of influenza virus-infected mice. T-cell receptor usage in the transgenic hybridomas was very restricted, with only one V alpha element used for ech of the two viral epitopes recognized. In the case of the hybridomas reactive to the nonstructural protein, sequence analysis showed that they all expressed V alpha 4J alpha 32 chains associated with the same junctional amino acids (Leu-Leu) that were encoded by five different nucleotide sequences, indicating a strong selection for T-cell receptor usage. Taken together, these data demonstrate that the available T-cell receptor repertoire can have a profound effect on the immunodominance of class I-restricted epitopes during a viral infection.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Base Sequence
- Bronchoalveolar Lavage Fluid/immunology
- Cytotoxicity, Immunologic
- Epitopes/analysis
- Epitopes/immunology
- Genes, MHC Class I
- Histocompatibility Antigens Class I/immunology
- Hybridomas
- Influenza A virus/immunology
- Interleukin-2/biosynthesis
- L Cells
- Lymph Nodes/immunology
- Mice
- Mice, Inbred CBA
- Mice, Transgenic
- Molecular Sequence Data
- Phenotype
- Receptors, Antigen, T-Cell/immunology
- Receptors, Antigen, T-Cell, alpha-beta/biosynthesis
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Species Specificity
- T-Lymphocytes/immunology
- T-Lymphocytes/virology
Collapse
|
research-article |
30 |
69 |